Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.

about

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.

Item

http://www.wikidata.org/entity/Q55658907

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Intralymphatic Glutamic Acid D ...... ical Trial in Type 1 Diabetes.

@en

Intralymphatic Glutamic Acid D ...... ical Trial in Type 1 Diabetes.

@nl

type

Item

label

Intralymphatic Glutamic Acid D ...... ical Trial in Type 1 Diabetes.

@en

Intralymphatic Glutamic Acid D ...... ical Trial in Type 1 Diabetes.

@nl

prefLabel

Intralymphatic Glutamic Acid D ...... ical Trial in Type 1 Diabetes.

@en

Intralymphatic Glutamic Acid D ...... ical Trial in Type 1 Diabetes.

@nl

P1476

Intralymphatic Glutamic Acid D ...... nical Trial in Type 1 Diabetes

@en

P2093

Jeannette Wahlberg

http://www.w3.org/2001/XMLSchema#string

Johnny Ludvigsson

http://www.w3.org/2001/XMLSchema#string

Peter Achenbach

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Intralymphatic immunization enhances DNA vaccination.

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Asso

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.

P304

9391845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/9391845

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30009185

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

5994289

http://www.w3.org/2001/XMLSchema#string